Novel immunotherapy leads to complete regression of chemotherapy-resistant liver cancer in 3-year-old

A caller study successful the New England Journal of Medicine by researchers astatine Baylor College of Medicine, Texas Children's Hospital and Seattle Children's describes a implicit regression of hepatoblastoma, the astir communal pediatric liver cancer, successful a 3-year-old treated with a caller immunotherapy.